MX2020010635A - Un derivado de oxopiridina sustituido. - Google Patents

Un derivado de oxopiridina sustituido.

Info

Publication number
MX2020010635A
MX2020010635A MX2020010635A MX2020010635A MX2020010635A MX 2020010635 A MX2020010635 A MX 2020010635A MX 2020010635 A MX2020010635 A MX 2020010635A MX 2020010635 A MX2020010635 A MX 2020010635A MX 2020010635 A MX2020010635 A MX 2020010635A
Authority
MX
Mexico
Prior art keywords
prophylaxis
diseases
amino
disorders
preparation
Prior art date
Application number
MX2020010635A
Other languages
English (en)
Spanish (es)
Inventor
Hartmut Schirok
Adrian Tersteegen
Mario Lobell
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MX2020010635A publication Critical patent/MX2020010635A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
MX2020010635A 2018-04-10 2019-04-03 Un derivado de oxopiridina sustituido. MX2020010635A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18166490 2018-04-10
PCT/EP2019/058398 WO2019197244A1 (en) 2018-04-10 2019-04-03 A substituted oxopyridine derivative

Publications (1)

Publication Number Publication Date
MX2020010635A true MX2020010635A (es) 2020-10-28

Family

ID=61965754

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020010635A MX2020010635A (es) 2018-04-10 2019-04-03 Un derivado de oxopiridina sustituido.

Country Status (17)

Country Link
US (1) US11884660B2 (enExample)
EP (1) EP3774796B1 (enExample)
JP (1) JP7333336B2 (enExample)
KR (1) KR102858566B1 (enExample)
CN (1) CN111902414B (enExample)
AU (1) AU2019251699B2 (enExample)
BR (1) BR112020018237A2 (enExample)
CA (1) CA3096480A1 (enExample)
DK (1) DK3774796T3 (enExample)
ES (1) ES2922533T3 (enExample)
IL (1) IL277811B2 (enExample)
MX (1) MX2020010635A (enExample)
PE (1) PE20210165A1 (enExample)
SA (1) SA520420308B1 (enExample)
SG (1) SG11202008352YA (enExample)
WO (1) WO2019197244A1 (enExample)
ZA (1) ZA202006963B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116874469B (zh) * 2023-09-06 2023-11-10 成都施贝康生物医药科技有限公司 一种氧代吡啶类化合物、中间体及其制备方法和用途
CN116947818B (zh) * 2023-09-18 2023-12-19 成都施贝康生物医药科技有限公司 一种氧代吡啶类化合物、中间体及其制备方法和用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
JP5419706B2 (ja) 2006-12-20 2014-02-19 タケダ カリフォルニア インコーポレイテッド グルコキナーゼアクチベーター
US9809545B2 (en) 2013-03-27 2017-11-07 Merck Sharp & Dohme Corp. Factor XIa inhibitors
TWI633089B (zh) 2013-03-28 2018-08-21 拜耳製藥股份有限公司 經取代的酮基吡啶衍生物
US9475809B2 (en) 2013-07-23 2016-10-25 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives and use thereof as factor xia/plasma
WO2015063093A1 (de) 2013-10-30 2015-05-07 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
WO2015120777A1 (zh) 2014-02-14 2015-08-20 四川海思科制药有限公司 一种吡啶酮或嘧啶酮衍生物、及其制备方法和应用
WO2016046158A1 (de) 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
WO2016046166A1 (de) 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
JP6517925B2 (ja) 2014-09-24 2019-05-22 バイエル ファーマ アクチエンゲゼルシャフト 置換されたオキソピリジン誘導体
ES2716417T3 (es) 2014-09-24 2019-06-12 Bayer Pharma AG Derivados de oxopiridina sustituidos con acción antiinflamatoria y antitrombótica
WO2016046156A1 (de) 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
ES2712886T3 (es) 2014-09-24 2019-05-16 Bayer Pharma AG Derivados de piridobenzazepina y piridobenzazocina que inhiben el factor XIa
CA2979937A1 (en) 2015-03-19 2016-09-22 Bayer Pharma Aktiengesellschaft Oxo-pyridine-derivatives as factor xia inhibitors for the treatment of thrombosis
JO3703B1 (ar) 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
EP3344618A1 (de) 2015-09-04 2018-07-11 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
CN113912586B (zh) 2016-08-31 2023-04-07 江苏恒瑞医药股份有限公司 氧代吡啶酰胺类衍生物、其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
CA3096480A1 (en) 2019-10-17
JP2021521132A (ja) 2021-08-26
KR20200141445A (ko) 2020-12-18
ES2922533T3 (es) 2022-09-16
BR112020018237A2 (pt) 2020-12-29
EP3774796A1 (en) 2021-02-17
AU2019251699A1 (en) 2020-09-24
CN111902414A (zh) 2020-11-06
US20210147414A1 (en) 2021-05-20
ZA202006963B (en) 2025-05-28
AU2019251699B2 (en) 2024-02-29
EP3774796B1 (en) 2022-04-27
IL277811B2 (en) 2023-12-01
US11884660B2 (en) 2024-01-30
PE20210165A1 (es) 2021-01-26
KR102858566B1 (ko) 2025-09-12
IL277811B1 (en) 2023-08-01
SG11202008352YA (en) 2020-09-29
SA520420308B1 (ar) 2022-09-29
JP7333336B2 (ja) 2023-08-24
WO2019197244A1 (en) 2019-10-17
CN111902414B (zh) 2023-08-04
DK3774796T3 (da) 2022-07-18
IL277811A (en) 2020-11-30

Similar Documents

Publication Publication Date Title
CO2018000113A2 (es) Compuestos derivados de 2-(4-fenil-2-oxopiridin-1-(2h)-il)alcanoilamina
NI202000083A (es) Derivados sustituidos de la carboxamida dihidropirazolo pirazina
NI201500143A (es) Derivados de oxopiridinas sustituida y usos de los mismos en el tratamiento de trastornos cardivasculares.
MX388140B (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
EP4335418A3 (en) Compositions and methods for treating pterygium
MX373658B (es) Derivado de acido 4-(4-(4-fenilureido-naftalen-1-il)oxi-piridin-2-il)amino-benzoico como inhibidor de quinasa p38.
MX2021007069A (es) 3,3-difluoroalilaminas o sales de las mismas y composiciones farmaceuticas que comprenden las mismas.
ECSP21043895A (es) Derivados de oxopiridina sustituidos
MX2018013797A (es) 5,6,7,8-tetrahidro[1,2,4]triazolo[4,3-a]piridin-3(2h)-onas y 2,5,6,7-tetrahydro-3h-pyrrolo[2,1-c][1,2,4]triazol-3-ones sustituidas su uso.
NI201700065A (es) 1-[2-(aminometil)bencil]-2-tioxo-1,2,3,5-tetrahidro-4h-pirrolo[3, 2-d]pirimidin-4-onas como inhibidores de mielopiroxidasa
MX374552B (es) Derivados de 2-fenil-3h-imidazo[4,5-b]piridina útiles como inhibidores de actividad de receptor huérfano similar a tirosina cinasa (ror1) de tirosina cinasa de mamífero.
ZA201907101B (en) Methods of preventing or treating ophthalmic diseases
AR051472A1 (es) Uso de inhibidores de las quinasas jun n- terminales para eltratamiento de la retinopatia glaucomatosa y enfermedades oculares
PL4028017T3 (pl) Pochodne 1,4-dihydrobenzo[d]pirazolo[3,4-f][1,3]diazepiny i powiązane związki jak modulatory kinazy lrrk2, nuak1 i/lub tyk2 do leczenia np. chorób autoimmunologicznych
SA520420308B1 (ar) مشتقة أكسوبيريدين تحمل بدائل
GEAP202115076A (en) Substituted 6-(1h-pyrazol-1-yl)pyrimidin-4-amine derivatives and uses thereof
WO2019040499A3 (en) Arf6 inhibitors and related methods